Improved glycemic control: In addition to weight loss, semaglutide helps improve blood sugar levels in patients with type 2 diabetes, reducing the risk of diabetes-related complications
O., et al
Long-Term Protocols: The most clinically relevant studies evaluated subcutaneous doses of 0.25 mg (250 mcg), 0.5 mg (500 mcg), and 1 mg (1,000 mcg) administered daily for 24 weeks
1 2 "First generic weight-loss injection approved in Canada", CTV News website , archived from the original on 30 June 2026 1 2 3 "Health Canada approves generic Ozempic from Apotex, country's largest drug maker", The Globe and Mail website , archived from the original on 1 May 2026 "Health Canada approves 2nd generic version of Ozempic and it's Canadian", The Canadian Press website , archived from the original on 15 May 2026 "1st generic semaglutide injection for weight loss approved: Health Canada", CBC News website , archived from the original on 30 June 2026 "Details for: SEVMIA", Drug and Health Product Portal , Health Canada, 29 June 2026, archived from the original on 29 June 2026 "Cheaper, generic versions of Ozempic could come to Canada as early as next year"
References American Society of Health-System Pharmacists
The other arrived more recently as a weekly injection promising weight loss, blood sugar control, and heart health